Use of the risk-rescue rating scale with adolescent suicide attempters: A cautionary note

The assessment of the medical lethality and intent of suicide attempts has been considered an important area of research for those interested in suicide. The current study examined the usefulness of the Risk-Rescue Rating Scale with 109 adolescent suicide attempters and found a restricted range of variability, which, in turn, resulted in poor interrater reliability on a number of items. Results suggest that the Risk-Rescue Rating Scale is of limited usefulness with adolescents, and alternative approaches to assessing lethality and suicidal intent with this age group are discussed.     

Total lymphoid irradiation in chronic polyarthritis--a new therapeutic concept

Eleven patients with refractory rheumatoid arthritis were submitted to a total lymphoid irradiation up to a dose of 20 Gy. A constant improvement of clinical symptoms was observed in four out of the eleven patients already during the treatment and in the other patients not later than two months after. The frequency of attacks decreased and the number of joints involved in the attack was reduced. Morning rigidity and joint swellings decreased. One patient developed joint empyemas 4 and 26 months after the treatment. Four patients died in the meantime. In two patients the cause of death were renal insufficiency and a postoperative cardiogenic shock associated with generalized amyloidosis. The third patient died because of a toxically induced left cardiac decompensation with sepsis that could not be controlled by antibiotic drugs and multiple joint empyemas. The fourth patient developed an abscess after surgical treatment of a Kaposi syndrome. She died three months later from acute left cardiac decompensation. The therapy induced a lymphocytopenia with decrease of T helper lymphocytes and unchanged number of T suppressor lymphocytes. The constant therapy results of total lymphoid irradiation in primary chronic polyarthritis is probably due to this modification in the immune regulation.     

Pharmakologische Wirkungen des Protamins Clupein

Zusammenfassung Das Protamin, Clupeinsulfat, besitzt schon in niedrigsten Konzentrationen die gleichen kolloid-osmotischen und adsorptiven Eigenschaften wie andere höhermolekulare Eiweißkörper. Bis zu 20 Clupeinsulfat verstärken die Kammertätigkeit des hypodynamen Froschherzens. Über 50 Clupeinsulfat bewirken systolischen Kammerstillstand. 0,5–5 Clupeinsulfat verstärken die Azetylcholinwirkung, größere Mengen setzen sie herab, erhöhen aber unter Umständen die Wirkungsdauer. Das Clupeinsulfat geht mit einigen höhermolekularen Eiweißkörpern Verbindungen ein, durch die diese Eiweißkörper eine Änderung in ihrer Löslichkeit, Dispersität und Adsorptionsfähigkeit erfahren.Mit 3 Textabbildungen (11 Einzelbildern).     

Das Nephron der Gymnophionen

Ohne ZusammenfassungMit 24 Textabbildungen.     

Tabische Fußveränderungen nach Unfall

Ohne Zusammenfassung Mit 4 Textabbildungen.     

Lepra

Ohne Zusammenfassung     

How I do it: endoscopic-microscopic anterior skull base reconstruction.

Reconstruction of the anterior skull base must be secure and watertight. Failure to achieve this places the patient at risk of the development of cerebral sepsis. We have developed the technique of endonasal duraplasty and have achieved a 90% long-term success rate. In this article we described the key elements of our technique starting with radiographic and fluorescein localization of a skull base defect. The main steps in reconstruction and materials used are detailed, together with modifications of our technique for certain difficult situations and tips for success. Attention is drawn to potential pitfalls that have been identified over 25 years of clinical practice.     

Adjunctive therapy with bromocriptine in Parkinson's disease

Patients with moderately severe Parkinson's disease complicated by the adverse effects of chronic levodopa use benefited from the addition of bromocriptine (Parlodel; Sandoz) in doses up to 26 mg daily, which allowed an approximate 30% reduction of levodopa dose. This resulted in a significant decrease in the amount of levodopa side-effects while maintaining or improving the original parkinsonian clinical stage. Increased effectiveness in these patients was not associated with increased dosage beyond 25-30 mg daily. When the doses of bromocriptine were increased slowly, the adverse reactions were minor and usually transient.